Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Randomized Study of Rivaroxaban vs Placebo on Disease Progression and Symptoms Resolution in High-Risk Adults With Mild Coronavirus Disease 2019
Jintanat Ananworanich, Robin Mogg, Michael Dunne, et al.
Clinical Infectious Diseases (2021) Vol. 75, Iss. 1, pp. e473-e481
Open Access | Times Cited: 43

Showing 1-25 of 43 citing articles:

Therapeutic strategies for COVID-19: progress and lessons learned
Guangdi Li, Rolf Hilgenfeld, Richard J. Whitley, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 6, pp. 449-475
Open Access | Times Cited: 382
COVID-19 and antimicrobial resistance: A cross-study
Sidra Ghazali Rizvi, Shaikh Ziauddin Ahammad
The Science of The Total Environment (2021) Vol. 807, pp. 150873-150873
Open Access | Times Cited: 119
2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19
Sam Schulman, Donald M. Arnold, Charlotte Bradbury, et al.
Journal of Thrombosis and Haemostasis (2024) Vol. 22, Iss. 6, pp. 1779-1797
Open Access | Times Cited: 18
Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper
Thomas Marjot, Christiane S. Eberhardt, Tobias Boettler, et al.
Journal of Hepatology (2022) Vol. 77, Iss. 4, pp. 1161-1197
Open Access | Times Cited: 62
COVID-19-Associated Pulmonary Embolism: Review of the Pathophysiology, Epidemiology, Prevention, Diagnosis, and Treatment
Luis Ortega‐Paz, Azita H. Talasaz, Parham Sadeghipour, et al.
Seminars in Thrombosis and Hemostasis (2022) Vol. 49, Iss. 08, pp. 816-832
Open Access | Times Cited: 28
Rivaroxaban for Prevention of Thrombotic Events, Hospitalization, and Death in Outpatients With COVID-19: A Randomized Clinical Trial
Gregory Piazza, Alex C. Spyropoulos, Judith Hsia, et al.
Circulation (2023) Vol. 147, Iss. 25, pp. 1891-1901
Open Access | Times Cited: 20
Intestinal Damage in COVID-19: SARS-CoV-2 Infection and Intestinal Thrombosis
Xiaoming Wu, Haijiao Jing, Chengyue Wang, et al.
Frontiers in Microbiology (2022) Vol. 13
Open Access | Times Cited: 25
Anticoagulation in COVID-19 patients – An updated systematic review and meta-analysis
Stefanie Reis, Maria Popp, Selina Schießer, et al.
Thrombosis Research (2022) Vol. 219, pp. 40-48
Open Access | Times Cited: 20
Rivaroxaban to prevent major clinical outcomes in non-hospitalised patients with COVID-19: the CARE – COALITION VIII randomised clinical trial
Álvaro Avezum, Haliton Alves de Oliveira, Precil Diego Miranda de Menezes Neves, et al.
EClinicalMedicine (2023) Vol. 60, pp. 102004-102004
Open Access | Times Cited: 11
Prophylactic anticoagulants for non-hospitalised people with COVID-19
Brena Costa Santos, Ronald Luiz Gomes Flumignan, Vinicius Tassoni Civile, et al.
Cochrane library (2023) Vol. 2023, Iss. 8
Open Access | Times Cited: 11
Anticoagulation in COVID-19 patients – An updated systematic review and meta-analysis
Stefanie Reis, Amon Faske, Ina Monsef, et al.
Thrombosis Research (2024) Vol. 238, pp. 141-150
Open Access | Times Cited: 3
Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial
John W. Eikelboom, Sanjit S. Jolly, Emilie P. Belley‐Côté, et al.
The Lancet Respiratory Medicine (2022) Vol. 10, Iss. 12, pp. 1160-1168
Open Access | Times Cited: 16
The Role of Heparin in COVID-19: An Update after Two Years of Pandemics
Marco Mangiafico, Andrea Caff, Luca Costanzo
Journal of Clinical Medicine (2022) Vol. 11, Iss. 11, pp. 3099-3099
Open Access | Times Cited: 15
To Anticoagulate or Not to Anticoagulate in COVID-19: Lessons after 2 Years
John G. Rizk, Aashish Gupta, Jose G. Lazo, et al.
Seminars in Thrombosis and Hemostasis (2022) Vol. 49, Iss. 01, pp. 062-072
Closed Access | Times Cited: 14
Prediction of tsunami of resistance to some antibiotics is not far‐fetched which used during COVID‐19 pandemic
Mandana Hosseini, Mohammed A. Hamad, Golazin Mohseni, et al.
Journal of Clinical Laboratory Analysis (2023) Vol. 37, Iss. 15-16
Open Access | Times Cited: 8
Cardiovascular drugs and COVID‐19 clinical outcomes: a systematic review and meta‐analysis of randomized controlled trials
Innocent G. Asiimwe, Sudeep Pushpakom, Richard M. Turner, et al.
British Journal of Clinical Pharmacology (2022) Vol. 88, Iss. 8, pp. 3577-3599
Open Access | Times Cited: 10
Evaluation of a fast‐and‐frugal clinical decision algorithm (‘pathways’) on clinical outcomes in hospitalised patients with COVID‐19 treated with anticoagulants
Benjamin Djulbegović, Iztok Hozo, David Lizarraga, et al.
Journal of Evaluation in Clinical Practice (2022) Vol. 29, Iss. 1, pp. 3-12
Open Access | Times Cited: 9
Safety and efficacy of antithrombotics in outpatients with symptomatic COVID-19: A systematic review and meta-analysis
Saad Ali Ansari, Nooraldin Merza, Madiha Salman, et al.
Current Problems in Cardiology (2024) Vol. 49, Iss. 4, pp. 102451-102451
Closed Access | Times Cited: 1
Thromboprophylaxis for outpatients with COVID-19: a Systematic Review and Meta-analysis
Cho‐Han Chiang, Omer Ahmed, Weitao Liu, et al.
Journal of Thrombosis and Thrombolysis (2024) Vol. 57, Iss. 5, pp. 784-787
Closed Access | Times Cited: 1
Association between antithrombotic therapy and mortality in patients hospitalized for COVID‑19
Xing Wang, Wuqian Chen, Jiulin Guo, et al.
Thrombosis Journal (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 1
Prognostic Significance of the Coagulation and Complement Systems in Critical COVID-19 Infection
Amitabha Ray, Kristen A. K. Winter, Dayalu S. L. Naik, et al.
Prague Medical Report (2023) Vol. 124, Iss. 2, pp. 77-93
Open Access | Times Cited: 3
Proposal for a Simple Algorithmic Approach to Manage Drug–Drug Interactions of Oral Anticoagulants with Nirmatrelvir/Ritonavir in COVID-19 Outpatients
John G. Rizk, Jose G. Lazo, Aashish Gupta, et al.
Seminars in Thrombosis and Hemostasis (2022) Vol. 49, Iss. 01, pp. 085-088
Open Access | Times Cited: 5
The efficacy and safety of out-hospital anticoagulation therapy with direct oral anticoagulant for COVID-19
Yu Geng, Chang Meng, Tong Gao, et al.
European Journal of Internal Medicine (2023) Vol. 115, pp. 160-163
Open Access | Times Cited: 2
Recommendations for the outpatient drug treatment of patients with COVID-19
Hanna Kaduszkiewicz, Michael M. Kochen, Stefan Kluge, et al.
Deutsches Ärzteblatt international (2022)
Open Access | Times Cited: 4
The role of direct oral anticoagulants in the era of COVID-19: are antiviral therapy and pharmacogenetics limiting factors?
Hrvoje Roguljić, Jerko Arambašić, Vjera Ninčević, et al.
Croatian Medical Journal (2022) Vol. 63, Iss. 3, pp. 287-294
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top